<DOC>
	<DOCNO>NCT01771289</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy neoadjuvant concurrent chemoradiation weekly docetaxel/cisplatin patient resectable IIIA-N2 NSCLC .</brief_summary>
	<brief_title>Neoadjuvant Concurrent Chemoradiation With Weekly Docetaxel/Cisplatin Resectable IIIA-N2 NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Patients age 18 year old . Present histologically proven cytological diagnosis NSCLC Stage IIIA define American Joint Committee Cancer Staging Criteria Lung Cancer , amenable surgery . No prior systemic chemotherapy target therapy lung cancer screening . ECOG performance status 0 1 . Life expectancy ≥12 week . Adequate hematological function : Absolute neutrophil count ( ANC ) ≥1.5 x 109/L , Platelet count ≥100 x 109/L , Hemoglobin ≥9 g/dL ( may transfuse maintain exceed level ) . Adequate liver function : Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) ; Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) ≤ 2.5 x ULN subject without liver metastasis ; ≤ 5 x ULN subject liver metastasis . Adequate renal function : Serum creatinine ≤ 1.25 x ULN , creatinine clearance ≥ 60 ml/min . Female subject pregnant breastfeeding . Patients prior exposure agent direct HER axis ( e.g . erlotinib , gefitinib , cetuximab , trastuzumab ) . Patients prior chemotherapy therapy systemic antitumour therapy ( e.g . monoclonal antibody therapy ) . History another malignancy last 5 year exception following : Other malignancy cure surgery alone continuous diseasefree interval 5 year permit ; Cured basal cell carcinoma skin cure situ carcinoma uterine cervix permit . Any unstable systemic disease ( include active infection , uncontrolled hypertension , unstable angina , congestive heart failure , myocardial infarction within previous year , serious cardiac arrhythmia require medication , hepatic , renal , metabolic disease ) . Known hypersensitivity Tarceva gemcitabine cisplatin . Eye inflammation eye infection fully treat condition predispose subject . Evidence disease , neurological metabolic dysfunction , physical examination laboratory find give reasonable suspicion disease condition contraindicate use investigational drug put subject high risk treatmentrelated complication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Lung Cancer</keyword>
</DOC>